IDMC Provides Positive Recommendation For Bio-Thera Solution's BAT4406F In Neuromyelitis Optica Spectrum Disorder Based On Interim Analysis Of Pivotal Phase II/III Trial
July 2 (Reuters) - Bio-Thera Solutions Ltd 688177.SS:
IDMC PROVIDES POSITIVE RECOMMENDATION FOR BIO-THERA SOLUTION'S BAT4406F (ADCC-ENHANCED ANTI-CD20 MAB) IN NEUROMYELITIS OPTICA SPECTRUM DISORDER BASED ON INTERIM ANALYSIS OF PIVOTAL PHASE II/III TRIAL
BIO-THERA SOLUTIONS LTD - TO CLOSE PATIENT ENROLLMENT AHEAD OF SCHEDULE
BIO-THERA SOLUTIONS LTD - IDMC RECOMMENDS EARLY TERMINATION OF BAT4406F TRIAL DUE TO EFFICACY
BIO-THERA SOLUTIONS LTD - TO FILE FOR REGULATORY APPROVAL FROM NMPA
BIO-THERA SOLUTIONS LTD - TO EXPLORE BAT4406F IN OTHER INDICATIONS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey





